Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB10.16 + Atezolizumab in HPV16+ Cervical Cancer
NCT04405349Phase 2Completed
- Sponsor
- Nykode Therapeutics
- Start
- Jul 2020
- Primary completion
- Nov 2023
- Modality
- Prophylactic Vaccines, DNA Vaccines, Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 2 trial of VB10.16 in Cervical Cancer (CC), sponsored by Nykode Therapeutics. Started Jul 2020; status: completed.
02
Drugs
VB10.16
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04405349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405349.